ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.494,89
-0,33%
S&P 500
5.360,79
0,26%
Dow Jones
38.868,04
0,18%
Euro vs US Dollar
1,07645
-0,13%
Bitcoin
69.600,02
-0,08%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Evaxion Biotech AS (EVAX)

  7. Evaxion Biotech AS (EVAX) News

EVAX

Evaxion Biotech AS (EVAX)

Evaxion Biotech AS
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:EVAX
DatumZeitQuelleÜberschriftSymbolFirma
07/06/202423h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
03/06/202415h25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
03/06/202414h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
03/06/202414h00GlobeNewswire Inc.Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024NASDAQ:EVAXEvaxion Biotech AS
28/05/202415h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
28/05/202414h21GlobeNewswire Inc.Evaxion Announces Business Update and First Quarter 2024 Financial ResultsNASDAQ:EVAXEvaxion Biotech AS
24/05/202422h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
23/05/202423h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
23/05/202423h00GlobeNewswire Inc.Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024NASDAQ:EVAXEvaxion Biotech AS
10/05/202423h29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
10/05/202423h00GlobeNewswire Inc.Evaxion Receives Nasdaq NotificationNASDAQ:EVAXEvaxion Biotech AS
06/05/202423h01Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:EVAXEvaxion Biotech AS
17/04/202414h00GlobeNewswire Inc.Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01NASDAQ:EVAXEvaxion Biotech AS
02/04/202413h00GlobeNewswire Inc.Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus InfectionNASDAQ:EVAXEvaxion Biotech AS
27/03/202412h30GlobeNewswire Inc.Evaxion Announces Business Update and Full Year 2023 Financial ResultsNASDAQ:EVAXEvaxion Biotech AS
19/03/202412h30GlobeNewswire Inc.Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ PlatformNASDAQ:EVAXEvaxion Biotech AS
29/02/202413h35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
29/02/202413h30GlobeNewswire Inc.Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology InnovationsNASDAQ:EVAXEvaxion Biotech AS
20/02/202413h32Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
20/02/202413h30GlobeNewswire Inc.Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSDNASDAQ:EVAXEvaxion Biotech AS
07/02/202422h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
07/02/202414h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
07/02/202414h30GlobeNewswire Inc.Evaxion Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:EVAXEvaxion Biotech AS
06/02/202414h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
06/02/202414h30GlobeNewswire Inc.Evaxion Announces Closing of $15 Million Public OfferingNASDAQ:EVAXEvaxion Biotech AS
05/02/202415h09Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:EVAXEvaxion Biotech AS
05/02/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
02/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EVAXEvaxion Biotech AS
01/02/202415h20Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
01/02/202415h20GlobeNewswire Inc.Evaxion Biotech Announces Pricing of $15 Million Public OfferingNASDAQ:EVAXEvaxion Biotech AS
 Showing the most relevant articles for your search:NASDAQ:EVAX

Kürzlich von Ihnen besucht

COIN
SOLUSD
Solana
AMEX
XLV
Health Care Select Sector
TG
LHA
Deutsche Lufthansa
AMEX
SPY
SPDR S&P 500
NASDAQ
GOOGL
Alphabet
TG
DTE
Deutsche Telekom
TG
MBG
MercedesBenz
NASDAQ
MSFT
Microsoft
TG
RHM
Rheinmetall
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
AMZN
Amazon.com
TG
ALV
Allianz
NASDAQ
AAPL
Apple
FX
EURGBP
Euro vs Sterling
AMEX
XLE
Energy Select Sector SPDR
USOTC
RHHBY
Roche (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten